The Duke University spinout has secured capital from 10 unnamed investors.
Istari Oncology, an oncology treatment developer spun out of Duke University, has obtained $1.1m in funding from a total of 10 undisclosed investors.
Founded in 2014 by Dani Bolognesi, Henry Friedman and Darell Bigner, Istari is developing a cure for recurrent glioblastoma, a type of brain tumour.
The company is based in Research Triangle Park, North Carolina, a research centre supporting projects from Duke University, North Carolina State University and University of North Carolina at Chapel Hill.
Bolognesi is the former chief executive of Aids drug company Trimeris and director of the Center for Aids Research at Duke. Friedman is a professor of pediatric oncology at Duke, while Bigner is a professor of cancer research.
A regulatory filing showed Istari is targeting a $2.9m final close for the round.
The spinout previously obtained $4m from unnamed backers in February 2017.
